Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its biologic therapeutic candidates ozekibart (INBRX-109) and INBRX-106. The company’s press releases and SEC reports describe ongoing clinical trials in solid tumors, including chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
On this page, readers can follow company-issued updates on key clinical milestones, such as topline and interim data from the registrational ChonDRAgon study of ozekibart in unresectable or metastatic conventional chondrosarcoma and expansion cohorts in colorectal cancer and Ewing sarcoma. Inhibrx Biosciences also reports on progress in its INBRX-106 Phase 2/3 trial in combination with pembrolizumab in head and neck squamous cell carcinoma and its Phase 1/2 trial in checkpoint inhibitor refractory or relapsed non-small cell lung cancer.
News items further cover financial results, capital arrangements, and corporate developments following the company’s spin-off from Inhibrx, Inc. and the sale of the INBRX-101 program to Sanofi S.A. Investors and observers can review earnings releases, descriptions of research and development spending, and commentary on the company’s clinical and regulatory plans.
Because Inhibrx Biosciences focuses on oncology and, in some communications, rare diseases, its announcements often highlight data from difficult-to-treat patient populations and regulatory designations, such as Fast Track and orphan drug status for ozekibart in chondrosarcoma. Bookmark this news feed to access the company’s own descriptions of trial outcomes, conference presentations, and other material events as they are disclosed.
Inhibrx, Inc. (Nasdaq: INBX) announced its fourth quarter and fiscal year 2020 financial results, highlighting a transformative year with advancements in four clinical programs. The Phase 1 study of INBRX-105 showed a maximum tolerated dose of 1 mg/kg, with 44% of evaluable patients achieving stable disease. Cash and cash equivalents grew significantly to $128.7 million at year-end. However, the company reported a net loss of $76.1 million for the fiscal year, worsening from a net loss of $51.4 million in 2019.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Guggenheim Healthcare Talks: 2021 Oncology Days, scheduled for February 12, 2021, at 2 p.m. Pacific Time. The presentation will be webcast live, accessible via the investor section of the Inhibrx website, and available for 60 days post-event. Inhibrx is focused on developing a pipeline of novel biologic therapies for oncology and orphan diseases, utilizing its proprietary sdAb platform and collaborating with companies like bluebird bio and Bristol-Myers Squibb.
Inhibrx, a clinical-stage biotechnology company, announced that the FDA granted Fast Track designation to INBRX-109 for treating patients with unresectable or metastatic conventional chondrosarcoma. This innovative therapeutic candidate is designed to induce tumor-selective programmed cell death through death receptor 5 (DR5). The designation facilitates the development and review process of drugs for serious conditions. A Phase 2 study of INBRX-109 is planned for mid-2021, aiming to demonstrate efficacy in enhancing patient outcomes where no approved therapies currently exist.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q3 2020 financial results, showing a net loss of $20.5 million, or $0.77 per share, slightly worse than the $20.2 million loss in Q3 2019. Cash and cash equivalents increased significantly to $127.7 million from $11.5 million at the end of 2019, bolstered by their recent IPO, which raised $126 million. The company expects multiple clinical data read-outs and new program initiations over the next two years, aided by an amended loan agreement with Oxford Finance LLC that enhances their financial flexibility.
Inhibrx, Inc. (Nasdaq: INBX) announced promising interim results from a Phase 1 clinical trial of INBRX-109, a treatment for chondrosarcoma, an orphan bone cancer. Out of 12 evaluable patients, 92% showed disease control, with 67% experiencing a reduction in tumor burden. Two patients had significant tumor size reductions of 60% and 32%. Favorable safety profiles were noted, with no serious adverse events reported. The company plans future discussions with the FDA for a registration-enabling study in Q2 2021, alongside expanding trials for other cancers.
Inhibrx, a clinical-stage biotechnology company (Nasdaq: INBX), announced its participation in several upcoming investor and scientific conferences. Presentations will occur at the:
- The 29th Annual Credit Suisse Virtual Healthcare Conference on November 12 at 3:30 p.m. ET,
- Jefferies Virtual London Healthcare Conference on November 17 at 2:10 p.m. ET,
- CTOS 2020 Virtual Annual Meeting on November 20 at 9:00 a.m. ET,
- Evercore's Annual Conference on December 3 at 3:30 p.m. ET.
Each event will be available via live webcast on their investor website.
Oxford Finance has closed a $10 million senior secured term loan to Inhibrx (Nasdaq: INBX), a clinical-stage biotech company. This funding, finalized on July 15, 2020, is aimed at supporting Inhibrx's growth as it transitions into a commercial-stage biotechnology firm. Inhibrx is focused on developing innovative biologic therapies, with a pipeline of four Phase 1 clinical trials targeting cancer and respiratory diseases. Oxford previously partnered with Inhibrx, highlighting confidence in its clinical advancements.
Inhibrx, a clinical-stage biotechnology company, has successfully completed its initial public offering (IPO) of 8,050,000 shares, including an over-allotment of 1,050,000 shares, priced at $17.00 per share. This IPO generated approximately $136.9 million in gross proceeds. The stock began trading on the Nasdaq under the symbol INBX on August 19, 2020. Jefferies, Evercore ISI, and Credit Suisse were the joint book-running managers for the offering, with LifeSci Capital serving as co-manager. The prospectus for this offering is available from the managing firms.